Johan Neyts is a full Professor at the Rega Institute (KU Leuven) in Leuven, Belgium. His team focuses on the development of novel antiviral strategies against a number of RNA viruses including flaviviruses (such as dengue and Zika), picornaviruses (rhino- and enteroviruses), coronaviruses, norovirus and others. His laboratory is a partner in several large EU funded consortia on the replication machinery of RNA viruses as targets to inhibit viral propagation and on the discovery and development of antivirals and vaccines. He has also successfully founded a biotech company in the field of antivirals for animals.
KU Leuven is the largest university in Belgium, ranking 45th in the Times Higher Education ranking (2020) of worldwide universities and 1st as European University in the Reuters Top 100 of the World’s most innovative institutions. KU Leuven employs ~9.000 researchers on its academic staff. KU Leuven Research & Development (LRD) is the technology transfer office (TTO) of the KU Leuven where a multidisciplinary team of experts’ guide researchers in their interaction with industry and society, and the valorisation of their research results (101 spin offs). The Rega Institute for Medical Research (KUL-REGA) host part of the Department of Microbiology, Immunology and Transplantation and the Medicinal Chemistry section of the Department of Pharmaceutical Sciences, having a long-standing expertise in antiviral drug discovery (Brivudine, Tenofovir).